"programmed death 1" trang 2 - tải miễn phí từ tailieunhanh
PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma

PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma
12    82    0
Expression and clinical significance of PDL1 and BRAF expression in nasopharyngeal carcinoma

Expression and clinical significance of PDL1 and BRAF expression in nasopharyngeal carcinoma
8    62    0
Increased PD-1-positive macrophages in the tissue of gastric cancer are closely associated with poor prognosis in gastric cancer patients

Increased PD-1-positive macrophages in the tissue of gastric cancer are closely associated with poor prognosis in gastric cancer patients
9    100    0
Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): Protocol for a multicenter phase II open label study

Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): Protocol for a multicenter phase II open label study
7    65    0
IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer

IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer
11    86    0
Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer

Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer
9    66    1
Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice

Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice
13    42    1
Amphotericin B suppresses M2 phenotypes and B7-H1 expression in macrophages to prevent Raji cell proliferation

Amphotericin B suppresses M2 phenotypes and B7-H1 expression in macrophages to prevent Raji cell proliferation
13    97    1
Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: A meta-analysis

Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: A meta-analysis
10    71    1
The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma

The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma
12    63    1
‘DURVIT’: A phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: Safety, toxicity and effect on the primary tumour and lymph node microenvironment

‘DURVIT’: A phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: Safety, toxicity and effect on the primary tumour and lymph node microenvironment
8    71    1
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: The multicentre prospective Safe Stop trial

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: The multicentre prospective Safe Stop trial
9    42    1
Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer

Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer
10    47    1
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic nonsmall cell lung cancer TRAP OLIGO study (WJOG11118L)

Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic nonsmall cell lung cancer TRAP OLIGO study (WJOG11118L)
6    38    1
Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: A retrospective study

Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: A retrospective study
9    55    3
Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer

Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer
10    16    1
Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: An exploration for expanded indications

Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: An exploration for expanded indications
8    19    1
Bioinformatic analysis of PD-1 checkpoint blockade response in infuenza infection

Bioinformatic analysis of PD-1 checkpoint blockade response in infuenza infection
13    19    1
Pembrolizumab-induced myasthenia gravis and myositis: Literature review on neurological toxicities of programmed death protein 1 inhibitors

Pembrolizumab-induced myasthenia gravis and myositis: Literature review on neurological toxicities of programmed death protein 1 inhibitors
6    3    1
Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: Treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)

Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: Treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)
6    1    1